Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Expression in Neoadjuvant Doxorubicin vs Docetaxel for Breast Cancer
NCT00123929Phase 2Completed
- Sponsor
- Hospital Clínico San Carlos
- Start
- Jan 2005
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Doxorubicin with Docetaxel (2 arms). Primary endpoint: Correlation of genetic tumoral pattern with response to docetaxel versus doxorubicin. Started Jan 2005; status: completed.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00123929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123929.